GlassScriptPhysician profile
Nanlong Liu
NPI 1619395977
$30,745.59
in general payments reported to CMS, 2019-2025
20 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $113 · 2021: $25K · 2022: $1,003 · 2023: $1,589 · 2024: $924 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737 · Travel and Lodging: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.23 |
| Travel and Lodging | $599.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26,093.53 | 2020-2025 | Exalt Model D, Apollo Esg System, Wallflex Duodenal |
| Apollo Endosurgery US INC | $967.32 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Abbvie INC. | $832.86 | 2019-2023 | |
| Medtronic, INC. | $501.38 | 2023-2025 | Pillcam, Gi Genius, Endoflip |
| Ardelyx, INC. | $246.29 | 2023-2025 | Ibsrela |
| Steris Corporation | $239.08 | 2019-2022 | |
| Janssen Biotech, INC. | $237.60 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.90 | 2019 | |
| Novo Nordisk INC | $191.67 | 2023-2025 | |
| 3-D Matrix, INC. | $159.74 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $156.14 | 2022-2024 | Eyemax |
| Olympus America INC. | $148.35 | 2023 | Evis Exera III Duodenovideoscope, Disposable Grasping Forceps, Endoclot Phs |
| Cook Medical LLC | $131.11 | 2022-2025 | Hemospray |
| E.R. Squibb & Sons, L.L.C. | $130.23 | 2023 | Zeposia |
| Genzyme Corporation | $124.74 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $120.84 | 2019 | |
| Dova Pharmaceuticals | $106.70 | 2019 | |
| Erbe USA INC | $100.00 | 2024 | |
| Gilead Sciences, INC. | $25.19 | 2024 | |
| Ethicon US, LLC | $18.92 | 2025 | Echelon Flex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanlong Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.